CompletedPhase 2NCT01498484
Therapeutic Effects of Epstein-Barr Virus Immune T-Lymphocytes Derived From a Normal HLA-Compatible Or Partially-Matched Third-Party Donor in the Treatment of EBV Lymphoproliferative Disorders and EBV-Associated Malignancies
Studying Epstein-Barr virus-associated malignant lymphoproliferative disorder
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Atara Biotherapeutics
- Principal Investigator
- Minoti Hiremath, MDAtara Biotherapeutics
- Intervention
- EBV-specific T cells (EBV-CTLs)(biological)
- Enrollment
- 87 target
- Eligibility
- All sexes
- Timeline
- 2011 – 2019
Study locations (1)
- Memorial Sloan Kettering Cancer Center, New York, New York, United States
Collaborators
Memorial Sloan Kettering Cancer Center
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01498484 on ClinicalTrials.govOther trials for Epstein-Barr virus-associated malignant lymphoproliferative disorder
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07381738Unrelated Cord Blood Transplantation for EBV-associated Lymphoproliferative DisordersFudan University
- RECRUITINGPHASE1, PHASE2NCT07450391EBV-AST Cell Injection for EBV-Associated Lymphoproliferative DisordersDaihong Liu
See all trials for Epstein-Barr virus-associated malignant lymphoproliferative disorder →